119 related articles for article (PubMed ID: 35636097)
1. Design, Synthesis, and biological evaluation of HDAC6 inhibitors based on Cap modification strategy.
Li X; Liu X; Wang S; Shi X; Lu M; Hao X; Fu Y; Zhang Y; Jia Q; He D
Bioorg Chem; 2022 Aug; 125():105874. PubMed ID: 35636097
[TBL] [Abstract][Full Text] [Related]
2. Do biological activities of selective histone deacetylase 6 (HDAC6) inhibitors rely on the modification of cap group?
Liu X; Wang S; Shi X; Lu M; Wang C; Li X; Zhang Y; Jia Q; Liu H
J Mol Recognit; 2022 Dec; 35(12):e2988. PubMed ID: 36054561
[TBL] [Abstract][Full Text] [Related]
3. Discovery of selective HDAC6 inhibitors based on a multi-layer virtual screening strategy.
Liu X; Yan W; Wang S; Lu M; Yang H; Chai X; Shi H; Zhang Y; Jia Q
Comput Biol Med; 2023 Jun; 160():107036. PubMed ID: 37196455
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, and Biological Evaluation of 2-Anilino-4-Triazolpyrimidine Derivatives as CDK4/HDACs Inhibitors.
Wang S; Han S; Cheng W; Miao R; Li S; Tian X; Kan Q
Drug Des Devel Ther; 2022; 16():1083-1097. PubMed ID: 35431540
[TBL] [Abstract][Full Text] [Related]
5. Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
Song H; Niu X; Quan J; Li Y; Yuan L; Wang J; Ma C; Ma E
Bioorg Chem; 2020 Apr; 97():103679. PubMed ID: 32120077
[TBL] [Abstract][Full Text] [Related]
6. Fragment-Based Drug Design of Selective HDAC6 Inhibitors.
Ruzic D; Djokovic N; Nikolic K
Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126
[TBL] [Abstract][Full Text] [Related]
7. Novel benzimidazole-linked (thio)barbiturates as non-hydroxamate HDAC6 inhibitors targeting leukemia: Design, synthesis, and structure-activity relationship.
Mansour RE; Abdulwahab HG; El-Sehrawi HM
Arch Pharm (Weinheim); 2023 Jun; 356(6):e2200433. PubMed ID: 36942938
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
Wang ZX; Wang S; Qiao XP; Li WB; Shi JT; Wang YR; Chen SW
Bioorg Med Chem; 2022 Nov; 74():117067. PubMed ID: 36272186
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and neuroprotective biological evaluation of novel HDAC6 inhibitors incorporating benzothiadiazinyl systems as cap groups.
Han B; Gu X; Wang M; Wang H; Sun N; Yang X; Zhang Q
Chem Biol Drug Des; 2024 May; 103(5):e14556. PubMed ID: 38772881
[TBL] [Abstract][Full Text] [Related]
10. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
12. Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
Feng T; Wang H; Su H; Lu H; Yu L; Zhang X; Sun H; You Q
Bioorg Med Chem; 2013 Sep; 21(17):5339-54. PubMed ID: 23820574
[TBL] [Abstract][Full Text] [Related]
13. Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo.
Li Y; Quan J; Song H; Li D; Ma E; Wang Y; Ma C
Bioorg Chem; 2021 Sep; 114():105081. PubMed ID: 34153811
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities.
Ding J; Liu J; Zhang Z; Guo J; Cheng M; Wan Y; Wang R; Fang Y; Guan Z; Jin Y; Xie SS
Bioorg Chem; 2020 Aug; 101():104023. PubMed ID: 32650178
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
Cheng C; Yun F; He J; Ullah S; Yuan Q
Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
[TBL] [Abstract][Full Text] [Related]
17. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety.
Al-Sanea MM; Gotina L; Mohamed MF; Grace Thomas Parambi D; Gomaa HAM; Mathew B; Youssif BGM; Alharbi KS; Elsayed ZM; Abdelgawad MA; Eldehna WM
Drug Des Devel Ther; 2020; 14():497-508. PubMed ID: 32103894
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells.
Yao D; Jiang J; Zhang H; Huang Y; Huang J; Wang J
Bioorg Med Chem Lett; 2021 Sep; 47():128204. PubMed ID: 34139324
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis and Biological Evaluation of a Phenyl Butyric Acid Derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 Inhibitor with Anti-proliferative Activity on Cervix Cancer and Leukemia Cells.
Rodríguez-Fonseca RA; Sixto-López Y; Fragoso-Vázquez MJ; Flores-Mejía R; Cabrera-Pérez LC; Vázquez-Moctezuma I; Rosales-Hernández MC; Bello M; Martínez-Archundia M; Trujillo-Ferrara JG; Becerra-Martínez E; Correa-Basurto J
Anticancer Agents Med Chem; 2017; 17(10):1441-1454. PubMed ID: 28044941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
